ESMO-Highlights zum metastasierten Mammakarzinom

Univ.-Prof. Dr. Wolfgang Janni (Ulm) ordnet im kompakten Überblick die wichtigsten Studienergebnisse zum mBC ein, die auf dem ESMO 2025 in Berlin vorgestellt wurden. Vor allem in der Therapie des Triple-negativen mBC bahnen gleich 2 Studien einen Standardwechsel an.

Interview & Redaktion: Dr. Silke Fanta

05.11.2025

Das Interview zum Mitlesen

(Ein Klick auf die Leitfragen öffnet das zugehörige Transkript)

Die wichtigsten ESMO-Präsentationen zum mBC

486MO - Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC).

Zum Abstract 486MO

LBA18 - Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest.
LBA19 - SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01).
LBA20 - Primary results from v: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i).
LBA21 - First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial.

Zu den Abstracts LBA18, LBA19, LBA20 & LBA21

Diese Inhalte werden präsentiert von

Das Interview zum Mitlesen

(Ein Klick auf die Leitfragen öffnet das zugehörige Transkript)

Die wichtigsten ESMO-Präsentationen zum mBC

486MO - Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC).

Zum Abstract 486MO

LBA18 - Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest.
LBA19 - SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01).
LBA20 - Primary results from v: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i).
LBA21 - First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial.

Zu den Abstracts LBA18, LBA19, LBA20 & LBA21